Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cells

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Li, Wenjuan ^a,b   Liu, Joan ^a   Jackson, Kasey ^a   Shi, Runhua ^a   Zhao, Yunfeng ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b HEBEI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE B; PYRUVATE KINASE; PYRUVATE KINASE M2; S6 KINASE; SHIKONIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NAPHTHOQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SINGLE DRUG DOSE; TUMOR VOLUME; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; BREAST NEOPLASMS; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; NAPHTHOQUINONES; PACLITAXEL;

EID: 84899433298     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094079     Document Type: Article

References (22)

1. Hou Y, Guo T, Wu C, He X, Zhao M (2006) Effect of shikonin on human breast cancer cells proliferation and apoptosis in vitro. Yakugaku Zasshi 126: 1383-1386. (Pubitemid 46089900)
2. Yang H, Zhou P, Huang H, Chen D, Ma N, et al. (2009) Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 124: 2450-2459.
3. Chen X, Yang L, Oppenheim JJ, Howard MZ (2002) Cellular pharmacology studies of shikonin derivatives. Phytother Res 16: 199-209. (Pubitemid 34534943)
4. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482. (Pubitemid 351766797)
5. Warburg O (1956) On the origin of cancer cells. Science 123: 309-314.
6. Wu Z, Wu L, Li L, Tashiro S, Onodera S, et al. (2004) p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. J Pharmacol Sci 94: 166-176. (Pubitemid 38405131)
7. Chen J, Xie J, Jiang Z, Wang B, Wang Y, et al. (2011) Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 30: 4297-4306.
8. Moody TW, Leyton J, Chan D, Brenneman DC, Fridkin M, et al. (2001) VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res Treat 68: 55-64.
9. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ (2004) Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 198: 591-599. (Pubitemid 38446534)
10. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, et al. (2002) Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277: 33490-33500. (Pubitemid 34984873)
11. Nguyen DM, Chen GA, Reddy R, Tsai W, Schrump WD, et al. (2004) Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. J Thorac Cardiovasc Surg 127: 365-375. (Pubitemid 38176639)
12. Cooper SJ, Bowden GT (2007) Ultraviolet B regulation of transcription factor families: roles of nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) in UVB-induced skin carcinogenesis. Curr Cancer Drug Targets 7: 325-334. (Pubitemid 46849237)
13. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH (1994) Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A 91: 609-613. (Pubitemid 24041451)
14. Liu G, Bode A, Ma WY, Sang S, Ho CT, et al. (2001) Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line. Cancer Res 61: 5749-5756. (Pubitemid 32769090)
15. Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194-204.
16. Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, et al. (2012) Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol 8: 839-847.
17. Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, et al. (2012) Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol 18: 4037-4043.
18. Andjelkovic M, Jakubowicz T, Cron P, Ming XF, Han JW, et al. (1996) Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci U S A 93: 5699-5704. (Pubitemid 26190743)
19. Kane LP, Mollenauer MN, Xu Z, Turck CW, Weiss A (2002) Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription. Mol Cell Biol 22: 5962-5974. (Pubitemid 34815843)
20. Gao N, Zhang Z, Jiang BH, Shi X (2003) Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310: 1124-1132. (Pubitemid 37237653)
21. Hay N (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183.
22. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22.